The paper by Wang and co-workers' in this issue of Thorax (pp 907-13) demonstrates a direct effect of postnatally administered dexamethasone on airway concentrations of surfactant proteins in preterm infants with idiopathic respiratory distress syndrome (IRDS). Compared with a control group, concentrations of the surfactant specific proteins SP-A and SP-D increased in tracheal aspirate samples during a 14 day period of dexamethasone treatment, while the albumin concentration concomitantly decreased. The authors propose that increased expression of SP-A and/or SP-D may be one mechanism of action when dexamethasone is used in attempts to prevent or palliate neonatal chronic lung disease. This paper is important and raises a number of intriguing questions, both about the role of surfactant components in postnatal lung disease and about the mode of action of glucocorticoid hormones in the lungs.
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There are limitations to this study which the authors acknowledge. Expression of results as absolute concentrations does not allow for variable aspirate dilution, but calculation relative to the variable concentration of albumin was evidently not appropriate. The authors only measured the hydrophilic protein components of surfactant, and provide no information about the phospholipid components which contribute predominantly to the surface properties of surfactant. Consequently it is not clear whether the steroid effect shown here was specific for surfactant proteins, or whether it represented a more general elevation of all surfactant components. Overall stimulation of surfactant production cannot be assumed, as increasing evidence suggests that the secretion of surfactant phosphatidylcholine and SP-A are regulated independently. older ages. Similarly, in human preterm infants given dexamethasone from 14 days of age, SP-A concentration in lung lavage samples only increased transiently for the initial day of treatment and then returned to control values. 4 All these considerations suggest that any effect of glucocorticoid hormones on expression of surfactant proteins is likely to be greatest in the immediate postnatal period, and that such a mechanism probably does not contribute to the therapeutic response to steroids in the mature lung. Furthermore, the significance of the contribution of increased synthesis of SP-A and SP-D to the improved lung function in response to dexamethasone in preterm infants is by no means clear, given the wide range of additional modes of action of steroids. These include decreased recruitment of inflammatory cells into the lungs, inhibition of secretion of inflammatory mediators such as prostaglandins and leukotrienes, and decreased elastase concentration. While dexamethasone is established as an effective treatment for established chronic lung disease, its role in the immediate postnatal period is more contentious. For instance, one recent study showed no clinical benefit when dexamethasone was given prophylactically over the first three days of life to preterm infants, and longer treatment schedules carry an increased risk of adverse effects.7 Such effects include enhanced risk of infection, decreased growth, and reduced alveolus formation. These complications are of less immediate importance in established chronic lung disease where there are few alternative treatments for a severe life threatening condition. They become more significant with early use of dexamethasone to prevent the inflammatory insult and reduce the incidence of chronic lung disease, as only a minority of preterm infants with IRDS will develop chronic lung disease.
With respect to surfactant function in the perinatal period, the roles for SP-A and SP-D are also unclear. In normal fetal lung development the synthesis, storage, and secretion of surfactant phospholipid increases considerably towards term. Moreover, the severity of RDS in preterm infants correlates with the magnitude of the deficiency of SP-A rather than that of disaturated phosphatidylcholine.'
In contrast, all currently available exogenous surfactant preparations for the effective treatment of RDS are based either on lipid extracts of natural animal surfactants or are completely synthetic. One limiting factor here is the lack of standardisation and availability of appropriate techniques with adequate sensitivities to quantify surfactant components in limited volumes of bronchoalveolar lavage samples available from clinical studies of disease states. Availability of antibodies has facilitated quantitation of SP-A and SP-D, as in the study by Wang et al,' but the wide variation in values between different groups probably reflects problems associated with antibody binding to heterogeneous lipid:protein complexes in comparison with purified protein standards. Measurement of SP-B and SP-C is more difficult as these lipid-soluble proteins are poorly immunogenic and established ELISA techniques are very insensitive. Most studies of phospholipid composition still rely on insensitive thin layer chromatography techniques, supplemented with measurement of disaturated phosphatidylcholine as the residue after destructive oxidation of unsaturated phosphatidylcholine species using osmium tetroxide. Several more specific and sensitive techniques have been developed, based on high performance liquid chromatography, mass spectrometry or NMR, but have yet to achieve widespread use in clinical studies. Some degree of standardisation may result from the task force set up by the European Respiratory Society to report on the current status of techniques for assay of acellular components in bronchoalveolar lavage samples, which is due to report towards the end of the year.
Hopefully the standardisation of analyses of lung surfactant composition and functions will facilitate the recognition of the contribution of this complex material to the maintenance of normal lung function, as well as to disease. It is very unlikely that, for instance, disruption of surfactant function will be identified as a major initiating factor in either asthma or cystic fibrosis, but it may well contribute to the severity of the subsequent disease process. Air pollutants, both gaseous and particulate, interact initially with the surfactant layer at the air:liquid interface in the lungs, and integrity of the surfactant system has been proposed as a major protective factor against oxidant-induced lung damage. All cellular reactions in the alveolus and airways take place within a surfactant enriched environment, and interaction of surfactant with cells must be considered in interpreting their various responses. At the very least, the adequacy of surfactant composition and function should be considered as one potential contributing factor in studies of diseases of the mature as well as the neonatal lung. One feature of such studies must be an integrated approach to determine the wide spectrum of surfactant components and functions in order to establish the extent of the contribution of surfactant dysfunction to respiratory diseases.
